Vortioxetine

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Feb 20, 2020 → Mar 12, 2022

NCT ID

NCT04288895

About Vortioxetine

Vortioxetine is a approved stage product being developed by Lundbeck for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04288895. Target conditions include Major Depressive Disorder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06604520	Phase 2	Recruiting	Mar 20, 2025	Sep 1, 2029	Fronto-temporal Dementia
NCT04294654	Approved	Completed	Feb 28, 2020	Jul 20, 2022	Major Depressive Disorder
NCT04288895	Approved	Completed	Feb 20, 2020	Mar 12, 2022	Major Depressive Disorder
NCT04220996	Approved	Completed	Dec 27, 2019	Mar 9, 2021	MDD
NCT03835715	Approved	Completed	Feb 5, 2019	Feb 21, 2020	Major Depressive Disorder
NCT03555136	Pre-clinical	Completed	Nov 17, 2017	Jan 31, 2021	Major Depressive Disorder
NCT03108625	Phase 3	Completed	Mar 1, 2017	Apr 16, 2020	Depressive Disorder, Major
NCT02871297	Phase 3	Terminated	Aug 17, 2016	Apr 19, 2022	Depressive Disorder, Major
NCT02332954	Approved	Completed	Feb 1, 2015	Jul 6, 2017	Major Depressive Disorder
NCT00707980	Phase 3	Completed	Jun 1, 2008	Aug 1, 2010	Major Depressive Disorder

Competing Products

20 competing products in Major Depressive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	23
LY2216684	Eli Lilly	Phase 1	33
LY2216684	Eli Lilly	Phase 1	33
Duloxetine	Eli Lilly	Phase 3	77
LY2216684 + Digoxin	Eli Lilly	Phase 1	33
Duloxetine + Paroxetine	Eli Lilly	Phase 3	77
Duloxetine + placebo	Eli Lilly	Phase 3	77
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	52
FK949E	Astellas Pharma	Phase 1	33
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	52
FK949E	Astellas Pharma	Phase 1	33
FK949E	Astellas Pharma	Phase 1	33
FK949E	Astellas Pharma	Phase 1	33
Mirtazapine Tablets	Sun Pharmaceutical	Approved	85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	52
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	52
Pramipexole ER + Escitalopram	Cipla	Phase 2	52
LY2216684 + Sertraline	Eli Lilly	Phase 1	33
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	33
LY2216684 + SSRI	Eli Lilly	Phase 3	77

Other Products from Lundbeck

memantine + memantine + placeboApproved

escitalopram + escitalopramApproved

BrexpiprazoleApproved

losartan (drug)Approved

vigabatrinApproved